Month: November 2022

The FDA has just approved Provention Bio’s Tzield™ (teplizumab-mzwv) – the first drug therapy that can delay the onset of type-1 diabetes (T1D) for those at risk of developing the […]

Let’s be honest. With the hectic pace of life, you might wonder why you should spend your precious time reading a newsletter, especially one about diabetes research. But have you […]